Modern Family star Julie Bowen thought she was ‘gonna die' after her health diagnosis at 29
The Modern Family star, 55, told Michael Rosenbaum on Tuesday's episode of his Inside of You podcast that she has sick sinus syndrome, a type of rhythm disorder that affects the heart's natural pacemaker, per the Mayo Clinic.
Bowen's condition is called hypervagotonia, which is increased activity in the vagus nerve, according to the National Institute of Health.
'I have a low resting heart rate,' she explained, noting that her pacemaker is 'set so that it can't go below 45.'
Before the pacemaker, Bowen's resting heart rate was in the 30s, when the 'normal' resting heart rate is between 60 to 100 beats per minute for women.
The Hysteria! star's sister diagnosed her condition while the two were on a getaway.
Bowen shared that her sibling, Annie Luetkemeyer, had just graduated from medical school and 'was at that time in her life when she, I guess, she always carried around a stethoscope. And we were on vacation, and she was like, 'I wanna listen to this.''
'She was like, 'That is not what they've been telling you, and it's not runner's heart or whatever. That means you need to go to a cardiologist,'' the Happy Gilmore star remembered.
'I was like, 'I'm fine,'' the actress shared, adding that her sister 'would not let it go.'
A month later, Bowen shot the pilot for the NBC series Ed alongside Tom Cavanagh. The comedy/drama ran from 2000 to 2004.
'I shot the pilot of Ed and immediately had to go get a pacemaker afterwards,' Bowen said. 'I was like, 'Oh my God. My life is over. This is so weird. I'm gonna die.' I don't know what I thought it was, because I was 29.'
'You're lucky you didn't die before that,' Rosenbaum, 52, responded.
'They said I wouldn't probably die of it, but I'd start passing out,' Bowen clarified. 'There was a vague feeling … whenever I was relaxed, really relaxed, I'd be, like, watching TV or movie.'
The Hubie Halloween star described it felt like she'd 'been holding my breath for a while, that feeling of, like, light-headedness. And they said, 'You're gonna be driving a car, and you're gonna pass out, and you're gonna kill somebody.' And I was like, 'Oh, well, then give me the Goddamn pacemaker.''
Bowen has had the batteries replaced three times; however, she admitted, 'I forget about it all the time.'
These days, the Boston Legal star hasn't let her condition slow her down one bit. In fact, she's starring in the upcoming sequel to the beloved 1996 sports comedy Happy Gilmore.
Bowen is reprising her role as Virginia Venit, the love interest of Adam Sandler's Happy Gilmore, but didn't know if she'd be asked back for round two.
'I thought, 'Well I won't be in it,'' Bowen told The Hollywood Reporter in June.
'And that was OK — it was like Virginia Venit, it's been 30 years, he's got a hottie. He's got some little bitty on the side, like a cart girl,' she continued. 'As a matter of fact my children told me, before I was even told officially that there was a Happy Gilmore sequel, my now 18-year-old said, 'Mum, I hear they're doing a sequel and he's with Sydney Sweeney as a cart girl.''
Bowen teased, 'I went, I'm hurt and I so respect that move. Of course, why wouldn't you? So when I got the call that I was actually in it, I was like, 'Are you sure? Come on.''
Although Sweeney, 27, isn't in the film, the sequel is set to have a slew of new faces, including Bad Bunny, Margaret Qualley, Benny Safdie, Travis Kelce, Kym Whitley and Eminem.
'Seeing Bad Bunny on set I was just like, 'Oh, I can't actually look you in the eye, I'm going to have to walk away,' and I did,' Bowen recalled.
'I think he was offended and I had to circle back and now I made it worse. I'm the kind of person who doesn't want to meet her heroes because I think I'm just going to be a jackass.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
19 hours ago
- News.com.au
Health Check: Amid headwinds, Nanosonics goes bells and whistles on core device
Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire Nanosonics (ASX:NAN) has launched updated iterations of its medical probe sterilising device Trophon, pending rollout of its all-new tool called Coris. The 'next generation' Trophon 3 has 40% faster cleaning cycles, with 'greater digital integration and the broadest traceability capabilities". The company has also launched Trophon 2 Plus, a tweaked version of an existing software upgrade for users of earlier Trophons. The company first commercialised the Trophons in 2009. Trophons clean ultrasound probes much more safely and reliably than traditional manual techniques. In mid-March the US Food & Drug Administration (FDA) approved the company's an all-new product Coris, for more fiddly flexible probes (such as for colonoscopies). The company expects to launch Coris in the US later this year. Nanosonics initially is launching the Trophon upgrades here and in the UK and Europe, with the FDA reviewing an approval submission. What the analysts think RBC Capital Markets analyst Craig Wong-Pan estimates only about 35% of the company's current US users have upgraded to a Trophon 2. "Therefore we believe there is a reasonable runway for further upgrade sales.' He's not sure whether the Trophon 3 features will convince enough hospitals to upgrade, given their budgetary pressures. 'Nonetheless, we believe the launch of these offerings is positive for Nanosonics, given the company has seen new competing products enter the ultrasound probe high level disinfection market.' RBC rates the company a 'hold' with a target price of $5. Meanwhile, broker Canaccord retains a 'buy' call, but has revised its target price from $5.74 to $5.15. The firm cites the impact of a competitor, Lumicare, which is not FDA approved but looks to be winning market share here. Canaccord expects Nanosonics to report 2024-25 revenue at the bottom of its cited $188.7 million to $193.8 million range. Amplia continues its winning ways One of the deadliest of tumours, pancreatic cancer is having its day in the sun courtesy of progress reports from Amplia (ASX:ATX) and OncoSil Medical (ASX:OSL). Amplia shares today vaulted a further 36%, having soared 25%, on Friday. That was after the company confirmed a 16 th 'partial response' in its phase 1b/2a advanced pancreatic cancer trial, called Accent. A confirmed partial response is when a tumour shrinks by more than 30% and the effect is sustained for two months or more. More to the point, Amplia earlier recorded two 'pathological complete responses' (PCRs). Rare in advanced pancreatic cancers, a PCR means there are no signs of cancer in tissue examined by a pathologist following surgical removal. Accent is evaluating Amplia's drug candidate narmafotinib, in combination with standard-of-care chemotherapies. Of the 55 patients enrolled, 20 of them remain on the trial so the company hopes for more positive responses. The trial is being conducted at seven sites in Australia and five sites in South Korea. Amplia shares have gained 330% since the start of the year. Oncosil completes trial enrolment Also on Friday, Oncosil said it had enrolled all 20 advanced pancreatic cancer patients in a phase I/II study of its eponymous targeted device. A novel brachytherapy for pancreatic and liver cancers, the treatment involves irradiating tumours via a direct injection, using endoscopic ultrasound guidance. Dubbed Pancosil, the study is investigating a novel percutaneous (through the skin) delivery for the spherical devices, guided by computed tomography. As investigator, The Amsterdam University Medical Center is conducting the study. Oncosil CEO Nigel Lange says the percutaneous approach could 'simplify administration and lower barriers to adoption, supporting wider market penetration and real-world clinical use'. The idea is not to cure the cancer, but reduce the tumors to the point where they are operable. Currently 30 countries have approved the device, including in the European Union, Britain, Turkey and Israel. The company should release preliminary Pancosil data in late 2025. Dimerix eyes other indications While the cashed-up Dimerix (ASX:DXB) remains focused on its phase III kidney disease program, it's eyeing secondary activities to broaden its portfolio. The company has raked in $65 million in upfront payments from four separate partnering deals for its lead indication, the regressive focal segmental glomerulosclerosis (FSGS). But not all the cash is needed to support the 286-patient phase III trial. 'Now that the funds have come in, we are in a very strong position and can turn attention to our pipeline,' CEO Dr Nina Webster says. She is working with the board on what program to pursue, but it will be 'in an area of high unmet need' and not too far from the company's expertise. 'Generally speaking, our competency is inflammatory disease and we understand rare diseases and kidneys well,' Webster says. We know for sure it won't be something like oncology injectables. Nor will it be diabetic kidney disease, which is much more prevalent than FSGS but a competitive field. In the meantime, Dimerix hopes it might be able to win accelerated FDA approval for FSGS, which the agency classes as an 'orphan' disease. … while PYC expands kidney disease trial Still on the topic of spuds. Following ethics approval, PYC Therapeutics (ASX:PYC) will advance to the second part of its safety and dosage study for polycystic kidney disease (PKD). PYC hopes its drug candidate, PYC-003 will address the underlying cause of PYC, the most prevalent monogenic disease in humans marked by extreme swelling of the organ. PYC will launch part B of the single ascending dose study of PKD patients, as well as escalating dosing to healthy volunteers. By combining existing ribonucleic acid (RNA) drug design with its proprietary delivery platform, PYC is developing precision therapies for patients with genetic diseases that have no treatment options. PYC's lead program is for the rare eye disease retinitis pigmentosa, but the company believes the kidney program shows much promise.
News.com.au
a day ago
- News.com.au
Five foods that can make you poop
Stuck in pur-gut-ory? You're not alone. While chronic stomach issues are worth getting checked out, a bit of bathroom bottleneck from time to time is normal — if not wildly unpleasant. The good news is that experiencing the anti-runs doesn't require a pharmacy run, as several foods can help clear your colon's traffic jam. 'As a gastroenterologist, I see patients struggle with constipation all the time,' Dr. Mikhail Yakubov of Manhattan Gastroenterology told The Post. 'While medications can help, the most natural first step is often what's on your plate.' Here are five foods that can gently get things rolling when your gut's on strike. Kiwis 'Kiwi is a hidden gem when it comes to gut health,' Yakubov said, noting that this fuzzy little fruit is 'rich in both soluble and insoluble fibre, but it also contains an enzyme called actinidin, which may help stimulate digestion.' According to Yakubov, one or two per day should be sufficient for most people and — as a bonus — it's 'low in sugar and doesn't cause bloating like some other fruits.' Oatmeal It's a fan favourite among fitness junkies for a reason. 'Oats are packed with soluble fibre — especially beta-glucan — which helps soften stool by drawing water into the bowel,' he said. 'This makes it easier to pass. A bowl of plain oatmeal in the morning is a great start,' Yakubov added. A recent study found that eating oatmeal regularly can also help reduce the risk of developing Type 2 diabetes, cardiovascular disease and obesity, so it's an all-round winner. 'Just skip the overly processed flavoured packets, which often have added sugar that can slow motility,' Yakubov suggested. Chia seeds 'These tiny seeds absorb many times their weight in water, forming a gel-like substance that bulks up and softens stool,' he said. 'They're also rich in omega-3s and fibre.' Yakubov recommends stirring a tablespoon or two into water, yoghurt or a smoothie for a healthy snack — just make sure to let them sit for at least 10 minutes to give them a chance to fully expand before eating. Coffee You're not imagining things — that morning cup of joe really can get things moving. 'It's not just a caffeine jolt; it actually stimulates the muscles of the colon,' he said. 'For some people, it works within minutes of drinking it. A cup in the morning can help jump-start the gut,' he added. However, Yakubov cautions that too much caffeine can have a dehydrating effect, making constipation worse in the long run, so best to pair your Java with plenty of water. Cooked spinach Ah, spinach — you think you've got tons of it until you cook it and it quickly dwindles down to nothing, mostly because it's 90 per cent to 95 per cent water. That's also part of what makes this nutritional powerhouse so healthy. 'Spinach is a good source of magnesium, which helps draw water into the intestines,' Yakubov said. 'It's also high in fibre and iron — especially important if constipation is linked to anaemia.' It's the perfect green to pair with your favourite protein. 'A half-cup of cooked spinach adds moisture and fibre to meals,' he said. And it makes for an even smoother ride than a salad. 'Cooked greens are generally easier to digest than raw for people prone to bloating,' he said. Fun fact: A full bag of fresh spinach (roughly 10 ounces) can cook down to just a cup or less of sauteed greens, so buy two. So what's the takeaway? 'Most foods that help relieve constipation fall into predictable categories: high-fibre fruits, seeds, leafy greens, whole grains,' he said. 'From a medical standpoint, there's not really a surprising 'magic' food that reliably helps people poop,' Yakubov said. But if he had to choose? 'I think the best one that fits your answer will be coffee.'
News.com.au
3 days ago
- News.com.au
Could giving up sex be the key to a stronger relationship?
The lights are off, and nobody's home — and apparently, that's a good thing. Turns out, a little less action in the bedroom might be the very thing keeping some couples together. While sexless marriages are usually viewed as a one-way ticket to splitsville, more couples are sharing that their love lives — minus the actual lovemaking — are happier than ever. Take Corey, who told Popsugar in a recent interview that after 13 years with her partner, their relationship reached a whole new high… without going low. 'During the time we weren't having sex, we were growing closer than ever,' Corey said. 'Sex is not the reason we are together; it's just a nice bonus.' The couple, who got together as hormone-fuelled teens, hit a dry patch post-Covid — between chronic fatigue, body image issues and plain ol' burnout. Eventually, they just stopped prioritising sex. 'We just kind of weren't in the mood,' Corey explained. 'We learned to communicate even better and genuinely didn't fight at all.' Instead of calling it quits, they cuddled, kissed, went on dates — and realised their connection didn't hinge on bedroom gymnastics. 'Our relationship is strong, and it's built on mutual respect and genuinely liking one another,' Corey told the outlet. Corey isn't alone. In a related Reddit post, one man raved about his six-year sexless marriage: 'The decision to stay has been the best of my life, by far. For the past few years, I wake up every day feeling so lucky to be next to such a wonderful partner.' And these couples may be more on-trend than they think. As previously reported by The Post, according to a government study analysed by the Institute of Family Studies, Americans are doing it less — or not at all. Sexlessness is soaring among 22- to 34-year-olds, with 24 per cent of men and 13 per cent of women saying they hadn't had sex in the last year. 'In sum, for young adult males, sexlessness has roughly doubled across all measures over the last 10 years,' the IFS noted. 'For young adult females, it has risen by roughly 50 per cent.' One major factor? Fewer folks are getting hitched — and those who are, aren't necessarily getting busy. Even inside marriages, some months are notoriously dry. Post-holiday stress, credit card bills and family drama all contribute to a nationwide libido nosedive. 'It's incredibly common for couples to experience a decline in intimacy during January,' relationship counsellor Simone Jobson told The Post. 'The holidays create a lot of external pressure… most people just need time to rest and recover.' But a cold winter doesn't always mean a cold relationship. As Corey proves, sometimes stepping back from sex helps couples find new ways to connect — and even make their way back to the bedroom. After two years of no sex, she and her beau recently started getting frisky again — but not out of guilt. 'Sex is a wonderful way to connect and feels great, but it doesn't have to be the basis of a marriage,' she said. Forget the seven-year itch — some couples are scratching their way to marital bliss by skipping the sheets altogether.
